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Abstract
The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing consid-
erably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of disease or on progression 
and to obtaining additional predictive information on immunotherapy efficacy. However, in up to 25% of cases, the initial 
tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not pos-
sible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alternatives are therefore 
required for molecular stratification, which includes liquid biopsy. This technique enables the evaluation of the tumour 
genomic profile dynamically and captures intra-patient genomic heterogeneity as well. To date, there are several diagnostic 
techniques available for use in liquid biopsy, each one of them with different precision and performance levels. The objec-
tive of this consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology is to 
evaluate the viability and effectiveness of the different methodological approaches in liquid biopsy in cancer patients and 
the potential application of this method to current clinical practice. The experts contributing to this consensus statement 
agree that, according to current evidence, liquid biopsy is an acceptable alternative to tumour tissue biopsy for the study 
of biomarkers in various clinical settings. It is therefore important to standardise pre-analytical and analytical procedures, 
to ensure reproducibility and generate structured and accessible clinical reports. It is essential to appoint multidisciplinary 
tumour molecular boards to oversee these processes and to enable the most suitable therapeutic decisions for each patient 
according to the genomic profile.
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Introduction
By the year 2030, 22.2 million new cases of cancer are 
expected worldwide: a challenge for cancer patient diag-
nosis and therapeutic approaches. Despite this increase, 
patient prognosis has improved with a gradual decrease in 
cancer-related mortality [1, 2], reflecting the breakthroughs 
in early diagnosis and cancer therapy. Therapeutic advances 
are mainly based on the understanding that cancer is a het-
erogeneous genomic disease [3]. This has boosted the devel-
opment of new tailored or precision therapeutic approaches 
that have a positive impact on patient survival.
The proportion of cancer patients with tumours harbour-
ing potentially targetable genomic abnormalities at the start 
of treatment or during progression has been growing over 
time. This is the basis for precision medicine, crucial for tak-
ing therapeutic decisions and for understanding the therapy-
induced dynamic evolution of the tumour [4]. At present, 
its use is considered standard in daily clinical practice for 
the treatment of some tumours [5], because it improves the 
outcome [6]. At the same time, drug approvals based on 
molecular abnormalities, regardless of the histology, have 
been enabled by precision oncology (tumour type-agnostic 
therapy approvals) [7]. Precision oncology has also helped 
to obtain information about predictive biomarkers, such as 
the tumour mutational burden (TMB), related to the efficacy 
of immune checkpoint inhibitors (ICI) in many cancer types 
[8]. * J. Remon  jordi.remon@delfos.cat
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This tailored treatment approach demands highly sensi-
tive and precise technologies for molecular stratification [9]. 
However, it is not possible to determine the molecular pro-
file in up to 25% of tumour biopsies, because the available 
tumour specimens do not meet the quality control criteria 
and have insufficient DNA for testing [9, 10]. Furthermore, 
biopsies provide limited information on the dynamics of 
tumour heterogeneity, as they can rarely be repeated sequen-
tially because of their location, the tumour size and the risk 
of complications related to the procedure.
Liquid biopsy, a term coined by Pantel and Alix-Pana-
bières [11], is a non-invasive diagnostic technique that can 
establish tumour molecular profile at the start of treatment 
and during progression, and can also capture dynamic intra-
patient genomic heterogeneity. Liquid biopsy includes test-
ing for circulating tumour DNA (ctDNA), circulating tumour 
cells or exosomes, platelet RNA and circulating tumour 
RNA (ctRNA) in different fluids such as plasma, pleural 
fluid, urine or cerebrospinal fluid, among others, although 
blood is the most commonly used [12], as described in 
Fig. 1. However, the results of the different analytical tech-
niques, including the most novel ones, have shown different 
levels of precision and performance in liquid biopsy [13].
One of the best developed forms of liquid biopsy in clini-
cal practice is that of ctDNA testing for different tumours. 
This consensus statement will therefore be focused on the 
clinical value of ctDNA testing.
The objective of this consensus statement is to provide a 
joint vision from the Spanish Society of Pathology (SEAP) 
and the Spanish Society of Medical Oncology (SEOM) on 
the challenges and possibilities associated with ctDNA test-
ing in cancer patients and to present physicians with precise 
and necessary information for decision making in daily clini-
cal practice.
Preanalytical requirements
Specimen types
Peripheral blood and, more precisely, plasma is the most 
widely used specimen in liquid biopsy, mainly because it 
is easy to obtain and to manage. ctDNA constitutes a minor 
fraction of circulating free DNA (cfDNA) and it contains 
tumour-specific genomic abnormalities. The variant allele 
frequency (VAF) is the percentage of each specific muta-
tion detected in cfDNA. The VAF can be very low in liquid 
biopsy, and it is therefore important to optimise preanalytical 
techniques to avoid false negatives.
The use of plasma sampling is preferred over serum for 
various reasons, even though the latter also contains ctDNA, 
such as the risk of cfDNA contamination from leukocyte 
lysis [14]. Furthermore, the ctDNA in serum samples can be 
partially adhered to a blood clot. Additionally, the platelet 
Fig. 1  Graphic description of 
the process during liquid biopsy
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component may be lost in blood samples and this can be an 
important source of tumour nucleic acids.
Collection
To obtain plasma, peripheral blood can be collected by 
venepuncture into tubes containing anticoagulant. The most 
widely used anticoagulant is ethylenediaminetetraacetic acid 
(EDTA), which inhibits DNase activity in the blood and is 
compatible with the polymerase chain reaction (PCR) test 
[15, 16]. The blood volume to be collected ranges from 15 
to 20 ml. However, smaller volumes can be used for testing, 
thanks to technological advances.
There are specific blood collecting tubes for stabilising 
the sample and optimising plasma collection. These tubes 
prevent the lysis of blood cells and contamination by non-
tumoral DNA for up to 1 week at a temperature of 22 °C 
[17]. However, some of these tubes contain ten times more 
additives than others (2.0 ml vs 0.2 ml), and this fact should 
be considered when calculating DNA yield [17].
Management of samples
It is important that once the blood is drawn, it is processed 
within the first few hours after collection, 4–6 h at most, if 
EDTA tubes are used. Holding the samples at room tem-
perature can cause massive lysis of blood cells, resulting in 
contamination with cfDNA [17]. This lysis is very obvious 
at 24 h, when the specimen has been stored at 22–24 °C 
[18–20]. Although some authors suggest that samples col-
lected in EDTA tubes could be stable for up to 24 h [21], 
the general recommendation is that they should be processed 
within the first 6 h after collection [19, 20].
In case that immediate processing is not possible, tubes 
with a cell stabiliser should be used to preserve the integrity 
of blood cells present in the sample. This will prevent cell 
death, rupture and/or genetic material release, as the latter 
can dilute the ctDNA and hinder testing.
Peripheral blood sample processing consists of cen-
trifugation for 10 min at 2800g and plasma separation fol-
lowed by a second centrifugation at 16,000g for 10 min to 
ensure that all cell residue is removed. The plasma is then 
transferred to 1.5–2.0 ml tubes, which preferably have low 
nucleic acid binding capacity. It is advisable to divide the 
plasma into small volume aliquots (1–2 ml each), to take 
only the necessary volume when used and without need-
ing to thaw all the available material, since cycles of freez-
ing–thawing affect nucleic acid integrity.
Storage and maintenance
According to published studies, storing frozen plasma before 
DNA extraction has no effect on subsequent ctDNA testing. 
For this reason, once the plasma is divided into aliquots, it 
should be stored frozen at – 20 °C for no more than 3 months 
or at – 80 °C if for longer periods (more than 3 months with 
no maximum period specification) [18].
Testing methods
Real time PCR (rtPCR) or quantitative PCR (qPCR)
RT-PCR or qPCR is a simple, quick and economic method 
for the relative quantification of somatic mutations, when 
compared against a control. The genomic alterations present 
in at least 10% of ctDNA can be detected with this tech-
nique [22]. Different types of qPCR have been developed 
to improve sensitivity: AS-PCR [23], AS-NEPB-PCR [24], 
PNA-LNA PCR clamp [25, 26] and COLD-PCR [27]. Most 
of these qPCR types are based on using an oligonucleotide 
that binds to the 3′ end of DNA to block amplification of 
the non-mutated allele and to promote amplification of the 
mutated allele. Alternatively, a step can be introduced in 
qPCR to enrich mutant allelic variants and facilitate their 
detection. AS-PCR is frequently used in clinical practice 
to detect single nucleotide variants or small insertions/
deletions in paraffin-fixed tissue. However, although it has 
98% specificity and 92% sensitivity with 96% concordance 
with the mutant allele in ctDNA samples [23], it is not the 
most adequate qPCR type for liquid biopsy. PNA-LNA PCR 
clamp has higher specificity, with a 0.1% detection limit of 
the mutant allele and 79% specificity [25, 26]. However, 
the most robust qPCR type for mutant variant detection is 
COLD-PCR, with a 0.1% detection limit and an enrichment 
of the mutant allele to improve the detection sensitivity of 
the technique up to 100 times [27].
Digital PCR (dPCR)
dPCR is a method that is more sensitive than qPCR. The 
sensitivity of this technique for mutant detection is close to 
0.1% and it is also a relatively economical, quick and sim-
ple method for absolute quantification of somatic mutations 
present in ctDNA [28]. The high sensitivity and specific-
ity of dPCR means that it is an especially useful technique 
for liquid biopsy. dPCR consists of distributing DNA from 
the specimen into thousands or millions of partitions made 
in oil droplets generated with a water–oil emulsion (digital 
droplet PCR [ddPCR]) [28, 29] or in multiple wells in a 
physical support [30]. Each partition contains one fragment 
of single-chain DNA, mutant or non-mutant, which will be 
clonally amplified by PCR. Mutant and non-mutant DNA is 
detected using fluorescent TaqMan® probes that can detect 
and quantify mutations that are very uncommon, but relevant 
in the tumour [31–33].
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BEAMing
Liquid biopsy using BEAMing technology (Beads, Emulsi-
fication, Amplification and Magnetics) is a system for non-
invasive study of tumour genotype based on the presence of 
ctDNA in peripheral blood. It is therefore possible to evalu-
ate the presence of mutations with prognostic or predictive 
value and also to quantify them.
After isolating the DNA, the regions of interest are ampli-
fied by PCR. Amplified DNA sequences are bound to mag-
netic beads impregnated with specific oligonucleotides and 
divided in millions of aqueous microdroplets in a water–oil 
emulsion, so that each microdroplet will contain only one 
DNA molecule and one magnetic particle. After subject-
ing the microdroplets to temperature cycles similar to con-
ventional PCR, each sequence is amplified again using the 
oligonucleotides as primers. After, the beads that are bound 
to thousands of DNA copies having the sequence of interest 
are collected.
Once this process has been completed, the aqueous phase 
is separated from the oily phase and the magnetic microbe-
ads are collected, purified and stained with specific fluo-
rophores to identify the mutant and non-mutant sequences 
due to their different fluorescence. Finally, the proportion 
of beads with mutant DNA compared with the control is 
determined by conventional flow cytometry [34, 35].
NGS
Next generation sequencing (NGS) technology allows par-
allel sequencing of millions of small DNA fragments. The 
sequences are then integrated using bioinformatics tools 
to detail the sequences of large genetic structures quickly, 
precisely and economically. Known mutations, as well as 
new mutations, fusions, abnormal gene copy number, muta-
tional burden or microsatellite instability can be detected by 
applying NGS techniques [36]. NGS-based liquid biopsy, 
unlike tissue NGS, requires a high sequencing depth, as 
well as incorporating molecular barcoding to differentiate 
errors in sequencing from real mutations and to achieve high 
sensitivity.
There are several approaches to NGS, the most important 
being sequencing by ligation and sequencing by synthesis. 
In the first case, the DNA sequence is obtained from the 
fluorescence emitted after hybridisation with fluorophore-
labelled probes (such as the Illumina® platform). DNA frag-
mentation and amplification is necessary before sequencing. 
In the case of Illumina®, sequencing is performed by PCR 
on a solid support. Hybridisation and the subsequent com-
plementary chain synthesis by DNA polymerase take place 
in a flow cell coated with two types of primers, one of them 
complementary to the DNA sequence. DNA is denatured 
and the final domain of the amplified fragment is bound to 
the second type of primer, creating a bridge that acts as a 
pattern that repeats the process thousands of times.
In the case of Ion Torrent®, changes in pH or fluores-
cence are produced, when new nucleotides are incorporated 
by polymerases and these are translated into the sequence. 
Amplification takes place in an emulsion, where DNA is 
bound to the specific primers inside microdroplets, generat-
ing thousands of sequences in each emulsion.
With regards to the sequencing step, cyclic reversible ter-
mination incorporates four fluorophore-labelled nucleotides 
that block the amplification process and are excited by a light 
source, with an intensity and wavelength that determine the 
synthesis sequence. The difference lies in the possibility of 
reversing the blockage, recovering the 3′-OH end, and there-
fore being able to continue adding nucleotides, to break the 
chemical bonds and eliminate the fluorophore attached to 
the nucleotide. This process takes place on large scale and 
in parallel in the cell.
In sequencing by synthesis by the addition of a single 
nucleotide or pyrosequencing, nucleotides are added in 
sequence. If the DNA polymerase incorporates the nucleo-
tide to extend the primer and afterwards pauses, an inorganic 
pyrophosphate is released that is then transformed in visible 
light by a series of enzymmatic reactions. A sensor detects 
the signal and depicts it in a pictogram, which allows the 
sequence to be determined. Before adding the next nucleo-
tide, an apyrase degrades the excess nucleotides from the last 
step to avoid inaccurate reactions [37, 38].
Table 1 shows the main advantages and disadvantages of 
testing methods that can be used in liquid biopsy.
Clinical validity and utility
The validity of liquid biopsy (measured as the capacity of 
a test to divide a population into groups with significantly 
different clinical results) and the clinical utility (measured as 
the capacity of a test to improve cancer diagnosis, treatment, 
management or prevention results) are the objectives of cur-
rent oncology studies on liquid biopsy [39, 40].
Early cancer detection
To date, liquid biopsy is not considered a sufficiently sensi-
tive or specific technique for early cancer detection in an 
asymptomatic population and cannot substitute for or com-
plement radiological tests. Despite this the potential of liq-
uid biopsy in this scenario is increasingly evident due to 
current technological advances. The exploratory validation 
of this technique is essential, as is the standardisation of 
preanalytical processes. To interpret the results correctly, it 
is important to consider the detection levels of the method to 
avoid false positives and to discern abnormalities that have 
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no oncogenic potential. It is also important that studies are 
conducted to compare case and control populations with an 
optimal population number.
Recently, a study conducted by the UK’s Early Cancer 
Detection Consortium (ECDC) has evidenced the need to 
standardise sample size, design and testing procedures in 
liquid biopsy studies before incorporating such strategies 
into screening programs [41].
However, most recent studies have shown that there is 
evidence of the potential utility of liquid biopsy in early 
cancer detection [42]. One example of this is the results 
of the Circulating Cell-free Genome Atlas (CCGA) study 
[43]. CCGA is a prospective cohort study designed for early 
cancer detection that will include 15,000 participants; 70% 
with a cancer diagnosis and 30% healthy participants, with 
no restrictions on comorbidities. In a planned case–control 
analysis with 2800 participants split into two groups: train-
ing group with n = 1406 (845 with different cancers, includ-
ing 118 lung cancer patients; and 561 non-cancer patients) 
and the independent group enrolling n = 834 (n = 472 cancer 
patients, including 46 lung cancer patients; and 362 non-
cancer patients), three methodologies for cfDNA detection 
have been used: (1) targeted sequencing of somatic muta-
tions; (2) whole genome sequencing (WGS) and; (3) whole 
genome bisulphite sequencing (WGBS) These three meth-
ods yield similar results. WGBS detected 41% of stage I, 
II, IIIA lung tumours and 89% of advanced stage tumours 
(IIIB–IV). WGS detected 30% of early stage tumours and 
87% of advanced tumours and targeted sequencing detected 
51% of early stage tumours and 89% of advanced tumours, 
showing that using cfDNA for lung cancer screening is a 
promising technique with a very low rate of false positives 
(< 1%).
The CancerSEEK panel has been developed for early 
detection in eight main cancers (ovaries, liver, pancreas, 
stomach, oesophagus, colorectal, breast and lung) and com-
bines the evaluation of 16 genes in ctDNA with a sensitivity 
between 69 and 98% and a specificity higher than 99% [42]. 
The role of liquid biopsy as a useful tool for early cancer 
diagnosis, alone or combined with other techniques, will be 
established by prospective validation with techniques that 
are standardised and that have good preanalytical controls.
Detecting residual disease in early disease
Early detection of tumour recurrences, after radical local 
treatment using dynamic ctDNA monitoring, poses a new 
challenge for early therapeutic decision making, which is, 
to date, based on clinical parameters and TNM staging. In 
localised disease, the proportion of detected ctDNA is lower 
than in advanced disease [44]. The persistence of ctDNA 
after radical treatment is correlated with the persistence 
of minimal residual disease (MRD) in many tumour types 
such as breast, lung or colon cancer. Detecting this type of 
ctDNA is correlated with a poorer prognosis and the diagno-
sis of relapse can be established before standard radiological 
procedures with high sensitivity and specificity [45–48]. If 
MRD could be detected through ctDNA, the population eli-
gible for adjuvant therapy could be better defined.
Table 1  Advantages and 
disadvantages of testing 
methods that can be used in 
liquid biopsy
BEAMing beads, emulsification, amplification and magnetics, ddPCR droplet-digital polymerase chain 
reaction, NGS next generation sequencing, qPCR quantitative PCR, rtPCR real time PCR
Technology Advantages Disadvantages
rtPCR or qPCR Quick Low sensitivity
Simple Low specificity
Economical Detects already known mutations
ddPCR High sensitivity Limited to multiplexing variant detection 
in a single reaction
High specificity Detects already known mutations
Quick
Simple
Relatively economical
BEAMing Quick Lacks validation?
Slightly invasive
Simple
Relatively economical
NGS High precision Complicated preparation of specimens
High reproducibility Limited to certain DNA regions
Detects new mutations Requires a complex bioinformatic analysis
Price progressively becoming 
lower
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The challenges in the development of future studies will 
include important methodological aspects that are not yet 
clarified, such as whether ctDNA should be measured using 
a binary variable (positive/negative) or a continuous one; or 
the standardisation of the data obtained from several studies, 
employing different techniques [49].
Molecular profile in advanced disease
The clinical validity of ctDNA testing using qPCR to detect 
EGFR mutations in non-small-cell lung cancer (NSCLC) 
and KRAS mutations in colorectal cancer (CCR) has been 
proven [50–52] and it has the approval of the FDA and the 
EMA.
Previously untreated advanced NSCLC is one of the 
main settings where ctDNA testing can be used in molecu-
lar profile analysis and, based on the results, for therapeutic 
decision making in clinical healthcare practice. The criteria 
for selecting the population eligible for molecular testing 
using ctDNA at diagnosis are the same ones as those rec-
ommended for tissue testing and they are gathered in the 
main national and international clinical guidelines. These 
criteria are: patients with advanced non-squamous NSCLC 
and squamous NSCLC with certain clinical characteristics 
(non-smokers, young patients…) that could be indicative of 
a potentially targetable genetic abnormality; when there is 
no tumour specimen available or one with low cellularity; 
or with inaccessible lesions for diagnosis or not worthwhile 
(bone lesions) as they require a dangerous procedure for 
obtaining the tumour specimen [53]. A negative ctDNA test 
result using a validated methodology should be confirmed 
in tumour tissue. Given the limited evidence of the clini-
cal validity, beyond the significance of ctDNA for studying 
mutations in EGFR in NSCLC and KRAS in CRC, and given 
the number of potentially targetable genetic alterations, there 
is a growing interest in using new strategies, such as NGS 
panels, although the experience is limited [54]. However, 
early studies show a good agreement with the genomic 
alterations obtained with tissue, although this agreement can 
be compromised by the variants detected in ctDNA with a 
VAF < 1% [55].
Diseases monitoring
ctDNA monitoring seems to be a possible alternative to 
imaging techniques. Changes in ctDNA levels can predict 
tumour progression with a difference of several months com-
pared with conventional methodology in some tumours [56]. 
The main applications of this technique include response 
monitoring, a better definition of questionable stable disease 
or disassociated response and even early response assess-
ment entailing a treatment change, without having to wait 
for weeks for radiological evaluation. There are various 
studies with limited numbers of patients conducted in dif-
ferent tumour types, as well as many retrospective studies, 
that have shown a good correlation between changes in 
ctDNA and response [56–58]. To implement ctDNA quan-
tification in daily clinical practice, further studies must be 
conducted to prove the efficacy and reproducibility of the 
methodology used and also the impact at a clinical level 
of the modified therapeutic approach based on biologi-
cal progression (according to ctDNA levels) with respect 
to conventional radiological progression. To date, there is 
insufficient evidence to recommend using liquid biopsy for 
disease monitoring or for therapeutic decision making based 
on this methodology.
Detecting resistance mechanisms
Many studies have been published that demonstrate that 
ctDNA can be used for emergency monitoring of resistant 
clones during exposure to a predetermined targeted treat-
ment strategy such as T790M mutation following treatment 
with EGFR tyrosine kinase inhibitors (TKIs), resistance 
mutations to ALK in patients carrying the translocation after 
exposure to ALK inhibitors [59], ESR1 mutations [60, 61], 
PIK3CA in breast cancer patients treated with different treat-
ment strategies, or KRAS mutations in colorectal carcinoma 
patients treated with anti-EGFR drugs [62–64]. Once again, 
a good example of how detecting one of the most common 
mechanisms of resistance (T790M) to first-generation or 
second-generation inhibitor drugs has been implemented in 
the context of clinical practice is advanced NSCLC with 
EGFR mutations, detected in ctDNA using Cobas® with a 
moderate sensitivity. This method has been recommended in 
national and international guidelines [53, 65]. Nevertheless, 
there are other techniques with greater sensitivity that can be 
adequate for detecting this acquired mutation.
An adequate and advisable technique is the use of NGS 
panels, since they increase the possibility of detecting resist-
ance mechanisms other than T790M, and therefore the treat-
ment can be tailored during progression. This is important, 
as third-generation inhibitors such as osimertinib are thera-
peutic options in first-line therapy for EGFR-mutant patients 
[66]. Using liquid biopsy, MET amplifications (15%) and 
EGFR mutations such as C797S (7%) have been reported 
as the major resistance mechanisms to osimertinib and this 
finding can enable clinical trials with targeted therapies 
according to the genomic profile during progression using 
NGS [67].
The role of liquid biopsy in immunotherapy
Liquid biopsy is a novel and promising research field in 
the search for predictive and prognostic biomarkers in 
immunotherapy.
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ctDNA levels can have a prognostic and predictive 
value in patients with advanced tumours treated with 
immunotherapy. In a small study of 19 metastatic mela-
noma patients treated with anti-CTLA-4 or anti-PD-1, 
ctDNA levels at baseline ≥ 10 copies/ml, were associ-
ated with a poorer prognosis than ctDNA levels < 10 
copies/ml (HR 6.3; p 0.017) [68]. In another study of 
advanced melanoma, patients treated with ICI, ctDNA 
levels detected at the start were associated with worse 
results in terms of progression free-survival (PFS) and 
overall survival (OS) in a univariate analysis [69]. Moni-
toring ctDNA levels could play a role in response moni-
toring and also in a current very uncertain clinical setting: 
detecting and differentiating pseudoprogression from true 
progression or even identifying hyperprogressors [68, 70, 
71]. Another application in the future could be detecting 
resistance mechanisms to ICI, such mutations in JAK2, 
CTNNB1, BRCA2, PTEN or B2M, that have been previ-
ously described as potential resistance mechanisms to 
several tumours treated with ICI and that can be detected 
in ctDNA [72].
With regard to predictive markers, a high TMB can 
increase the appearance of neoantigens, thereby enhanc-
ing immunotherapy response. In fact, measuring TMB in 
tumour tissue has shown a predictive potential in several 
tumour types [73, 74]. At the same time, a significant 
effort has been devoted to measuring TMB retrospectively 
in peripheral blood (bTMB) in many tumour types and to 
estimate its predictive value. Recently, bTMB data from 
two prospective studies have been published. The studies 
were conducted in previously treated advanced NSCLC 
patients and compared docetaxel with atezolizumab. In 
these studies, a high bTMB was correlated with a benefit 
in PFS with immunotherapy [75]. It is important to note 
that in the study, a high bTMB was not correlated with 
PD-L1 expression levels. In this regard, the results of the 
B-FIRST [76] study have recently been published. This 
study is the first prospective study evaluating bTMB as a 
predictive biomarker in advanced NSCLC patients treated 
with atezolizumab monotherapy as first-line therapy. The 
results of this analysis have shown that greatest benefits 
in PFS are seen in patients with high bTMB and have 
better responses with atezolizumab versus chemotherapy, 
but not in OS [76]. Considering this data, the consensus is 
that, to date, there is not enough evidence to recommend 
the use of liquid biopsy in immunotherapy, since there is 
a lack of standardisation in the technique for detecting 
bTMB as well as in the cut-off points for defining high 
bTMB.
Table 2 shows a summary of the validity and clinical 
utility of liquid biopsy at different points in the disease 
course.
Interpreting the results
ctDNA coexists with cfDNA. The feasibility of liquid biopsy 
depends on the amount of detected ctDNA, although differ-
ent factors such as the amount and site of metastases (except 
in patients with metastatic brain disease), the cell prolifera-
tion index, the apoptosis rate, the genomic instability or the 
amplification of a gene associated with a mutation can be 
limiting factors [45, 77]. These limitations could explain the 
differences between the results obtained in liquid biopsy and 
those obtained with tissue [44]. Therefore, it should be borne 
in mind that a negative liquid biopsy test does not necessar-
ily mean an absence of a genomic abnormality.
The growing application of quantitative techniques, such 
as NGS or the different versions of dPCR, has reduced the 
limitations mentioned above. These techniques can detect 
mutations and quantify a mutation frequency using VAF. 
Sequential evolution in the VAF variants of a patient’s 
genomic alterations can be considered as a longitudinal 
marker to replace tumour evolution or therapeutic response. 
Tumour heterogeneity can be detected with liquid biopsy 
[78] and with the VAF of the differently detected abnormali-
ties and the coexistence of dominant clones, indicative of 
the responsiveness to a targeted therapy can be established 
[79, 80] as well as the coexistence of sub-clonal alterations 
with uncertain significance or that can be associated with a 
poorer prognostic [81].
The portfolio of targeted therapies includes the treat-
ments approved for specific molecular alterations as well as 
experimental drugs that have limited preclinical evidence 
[82]. As NGS techniques provide more information, inter-
preting and prioritising clinically relevant genomic altera-
tions poses a significant challenge. Another critical aspect in 
precision oncology is defining standardised bioinformatics 
procedures and developing algorithms that determine which 
genetic alterations should guide the selection of a targeted 
therapy [83]. It is therefore crucial and a real challenge to 
create multidisciplinary tumour molecular boards focused on 
genomic profiling tests for tumours. These boards will help 
providing objective interpretations of results that follow any 
Table 2  Validity and clinical utility of liquid biopsy in clinical prac-
tice
CRC colorectal cancer, NSCLC non-small cell lung cancer
Approval status
Screening Not approved
Minimal residual disease Not approved
Advanced disease Approved for NSCLC and CRC 
Disease monitoring Not approved
Resistance mechanisms Approved for T790M in NSCLC
Immunotherapy Not approved
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of the current classifications or consensus statements based 
on scientific evidence [84] and that make a real impact in 
therapeutic decision making. For this purpose, it is impor-
tant that the results reported from the ctDNA test are precise 
and clear so that the necessary information for therapeutic 
decision making is transmitted. Apart from patient and sam-
ple identification data, the report should include the details 
regarding the method used, the analytical characteristics of 
the assay, the sensitivity or detection limit of the mutated 
allele and the VAF, if available in that assay [85, 86].
Likewise, there are still important technical and ethical 
barriers that should be evaluated before implementing NGS 
in clinical practice. In this respect, the same genomic altera-
tion can have distinct therapeutic implications in different 
tumour contexts [87]. Furthermore, not all somatic vari-
ants detected in plasma are derived from the tumour. Some 
mutations can be related to clonal haematopoiesis processes 
[88, 89] that are more frequent from the fifth decade of life, 
occurring in up to 10% of healthy individuals 70 years of 
age or older [90–92]. ctDNA testing using NGS can detect 
both somatic and germline variants, the latter characterised 
by a VAF were higher than 50%. Finally, the psychologi-
cal impact on the patient should be considered, when non-
targetable genomic alterations are detected.
Other considerations
Informed consent
The informed consent form should be precise, concise and 
accessible. Liquid biopsy is a rapid growth field in oncology 
and NGS techniques in ctDNA can provide a substantial 
amount of genomic information, including germline muta-
tion detection in ctDNA in up to 1.4% of cases, especially 
in patients younger than 50-years old for all tumour types 
[93]. In this context, healthcare professionals can face an 
ethical dilemma, when revealing germline results detected 
in liquid biopsy that do not have a repercussion in practice 
[94], but that can have a psychological impact on the patients 
and their families [95]. The informed consent should include 
these considerations, and both the patients and their families 
should be advised about this. The patient should also express 
if he/she wants to know the result, in case a germline altera-
tion was detected. Widespread use of NGS can increase inci-
dental detection of germline mutations in cfDNA and it can 
become an important challenge in coming years, requiring 
collaboration from Genetic Committee units. However, it 
is worth noting that, to date, germline mutations detected 
in cfDNA should not replace validated genetic testing for 
hereditary cancer. Finally, the document should note that 
there is a possibility that conducting these tests does not 
detect an alteration or that the detected alterations could 
potentially not be targetable at present.
Quality control
Quality control during the test phase should be conducted 
routinely to predict and prevent procedural failures and to 
detect possible false negatives.
The technical procedure (e.g. dPCR, NGS) should be 
validated to simulate the clinical environment. Further-
more, the assay sensitivity and specificity should be robust, 
reproducible and should have proper internal and external 
quality controls [13, 19, 96, 97]. Comparisons with paired 
tissue specimens should have the same characteristics. Some 
authors (89) suggest using synthetic controls that imitate the 
DNA in the patient’s plasma [98].
Taking part in external quality programs (EQA) is essen-
tial, both for the preanalytical phase already discussed as 
well as for the quantification and genotyping methodology. 
There are several providers or associations for validating the 
technique: European Molecular Genetics Quality Network 
(EMQN), European Society of Pathology (ESP), EQA and 
the United Kingdom National External Quality Assessment 
Service (UK NEQAS) for Molecular Genetics, sponsored by 
the International Network for Pathology (IQN Path) [96, 97].
Conclusions
In some tumours, liquid biopsy is a valid alternative to 
current standard procedures, offering rapid, precise and 
dynamic information that can complement the information 
offered by a tumour biopsy. It can describe the heterogeneity 
of the tumour and it can also provide relevant information 
for therapeutic decision making at baseline and during pro-
gression. For this reason, in some tumours and according 
to current evidence, liquid biopsy is considered to be an 
acceptable alternative to tumour tissue biopsy.
To gain wide acceptance and increase implementation of 
liquid biopsy in routine practice by professionals that treat 
cancer patients, it is important to standardise preanalytical 
and analytical procedures, so they are reproducible and also 
to generate structured and accessible reports. Multidisci-
plinary tumour molecular boards focused on evaluating the 
genomic profile of the tumour are necessary for this pro-
cess to validate and integrate the genomic profiling results 
in the clinical setting. The potential applications of ctDNA 
such as early diagnosis, screening or molecular residual dis-
ease detection are the challenges for the future, as they can 
increase the utility of these techniques in the early stages of 
cancer. Detecting the mechanism of acquired resistance to 
various tailored treatments is also a challenge in advanced 
disease. Therefore, improving our knowledge on the clinical 
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utility of liquid biopsies will help to implement this tech-
nique in the broad management of cancer patients.
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